Graham-Field Health Products, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Replacement $35 mil. "debtor-in-possession" financing agreement with Congress Financial Corporation closes April 17. The new financing arrangement replaces the current DIP loan serviced by IBJ Whitehall Business Credit Corporation, secured following a Chapter 11 bankruptcy filing in Delaware federal court, and includes more favorable terms (1"The Gray Sheet" Jan. 10, p. 10). "It is obvious that the financial community has strong faith in the company's ability to emerge from its Chapter 11 voluntary bankruptcy position as an on-going concern," CEO David Hilton commented
You may also be interested in...
Graham-Field
"Debtor-in-possession" credit facility for up to $38.8 mil. is secured following the filing of a voluntary Chapter 11 bankruptcy petition in Delaware federal court. The financing will provide the medical/surgical supply maker and distributor with sufficient liquidity to pay suppliers for "post-petition" goods and services, meet payroll, and carry it through completion of its debt restructuring, the firm says. The bankruptcy petition coincides with the resignations of John McGregor as president and CEO, and of Robert Gluck as chief financial officer. David Hilton was named to replace McGregor. Hilton is known as a turn-around specialist and formerly headed J.E. Morgan Knitting Mills. Rothschild, Inc. has been retained to provide investment-banking services
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.